MedTrace Logo

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

NCT01655836 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-09-11

No results posted yet for this study

Summary

The first technology is called high dose rate brachytherapy. Brachytherapy is sometimes called internal radiation therapy. High dose rate brachytherapy is a procedure that involves temporarily placing radioactive material inside the patient's body for about 10-20 minutes. Then, the remainder of the radiation treatment will be given over a 3 week period using stereotactic body radiation therapy (SBRT). SBRT is a novel treatment modality that involves the delivery of very high individual doses of radiation to tumors with high precision. This allows the doctor to deliver the same amount of radiation in a much shorter time. The purpose of this study is to determine the safety of brachytherapy when combined with hypofractionated SBRT.

Conditions

  • Prostate Cancer
  • Adenocarcinoma of the Prostate
  • Recurrent Prostate Cancer
  • Stage IIA Prostate Cancer
  • Stage IIB Prostate Cancer

Interventions

RADIATION

Brachytherapy

Undergo high dose rate brachytherapy

RADIATION

Stereotactic Body Radiation Therapy

Undergo stereotactic body radiation therapy

PROCEDURE

Quality-of-life assessment

Ancillary studies

OTHER

Questionnaire administration

Ancillary studies

Sponsors & Collaborators

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Robert Den, MD · Thomas Jefferson University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-04
Primary Completion
2016-07-27
Completion
2040-01-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01655836 on ClinicalTrials.gov